Weiqi Gao1, Shuangshuang Lu1, Yufei Zeng1, Xiaosong Chen2, Kunwei Shen3. 1. Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China. 2. Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China. chenxiaosong0156@hotmail.com. 3. Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China. kwshen@medmail.com.cn.
Abstract
PURPOSE: This study aimed to evaluate whether axillary lymph node dissection (ALND) can be omitted in patients with 1-2 positive sentinel lymph nodes (SLNs) who received total mastectomy (TM). METHODS: Consecutive breast cancer patients with 1-2 positive SLNs were retrospectively reviewed from a multi-institutional database. Patients were divided into sentinel lymph node biopsy (SLNB) group and ALND group. Administration of adjuvant chemotherapy and survival were compared between groups. To further verify the results, a meta-analysis was also conducted. RESULTS: Among the 1161 enrolled patients, 893 (76.9%) received ALND and 268 (23.1%) underwent SLNB alone. Administration of chemotherapy was comparable between the two groups (91.1% vs. 90.6%, P = 0.798), which was consistent in TM (P = 0.638) and BCS cohort (P = 0.576). After a median follow-up of 36 months, no significant difference was observed between the two groups in recurrence-free survival (P = 0.583) regardless of surgery of breast. During further meta-analysis, 13 out of 4733 relative studies reported the association of axillary surgery and disease-free survival (DFS) or overall survival (OS) in 1-2 positive SLNs patients. Pooled analysis showed no difference in adjusted DFS (HR 0.84, 95% CI 0.70-1.02) or OS (HR 1.02, 95% CI 0.93-1.11) between SLNB and ALND groups. Survival benefit of ALND remained non-significant after restricting the analysis in four studies with patients only receiving BCS, or in three studies with patients only receiving TM. CONCLUSION: Further ALND does not impact adjuvant chemotherapy administration or disease outcome in breast cancer patients with 1-2 positive SLNs treated with TM.
PURPOSE: This study aimed to evaluate whether axillary lymph node dissection (ALND) can be omitted in patients with 1-2 positive sentinel lymph nodes (SLNs) who received total mastectomy (TM). METHODS: Consecutive breast cancer patients with 1-2 positive SLNs were retrospectively reviewed from a multi-institutional database. Patients were divided into sentinel lymph node biopsy (SLNB) group and ALND group. Administration of adjuvant chemotherapy and survival were compared between groups. To further verify the results, a meta-analysis was also conducted. RESULTS: Among the 1161 enrolled patients, 893 (76.9%) received ALND and 268 (23.1%) underwent SLNB alone. Administration of chemotherapy was comparable between the two groups (91.1% vs. 90.6%, P = 0.798), which was consistent in TM (P = 0.638) and BCS cohort (P = 0.576). After a median follow-up of 36 months, no significant difference was observed between the two groups in recurrence-free survival (P = 0.583) regardless of surgery of breast. During further meta-analysis, 13 out of 4733 relative studies reported the association of axillary surgery and disease-free survival (DFS) or overall survival (OS) in 1-2 positive SLNs patients. Pooled analysis showed no difference in adjusted DFS (HR 0.84, 95% CI 0.70-1.02) or OS (HR 1.02, 95% CI 0.93-1.11) between SLNB and ALND groups. Survival benefit of ALND remained non-significant after restricting the analysis in four studies with patients only receiving BCS, or in three studies with patients only receiving TM. CONCLUSION: Further ALND does not impact adjuvant chemotherapy administration or disease outcome in breast cancer patients with 1-2 positive SLNs treated with TM.
Authors: Jiwoong Jung; Wonshik Han; Eun Sook Lee; So-Youn Jung; Jai Hong Han; Dong-Young Noh; Yumi Kim; Hee Jun Choi; Jeong Eon Lee; Seok Jin Nam; Jong Won Lee; Hee Jeong Kim; Eunhae Um; Joo Heung Kim; Seho Park; Young Up Cho Journal: Breast Cancer Res Treat Date: 2019-02-04 Impact factor: 4.872
Authors: Min Yi; Sharon Hermes Giordano; Funda Meric-Bernstam; Elizabeth A Mittendorf; Henry M Kuerer; Rosa F Hwang; Isabelle Bedrosian; Loren Rourke; Kelly K Hunt Journal: Ann Surg Oncol Date: 2010-09-19 Impact factor: 5.344
Authors: Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow Journal: JAMA Date: 2011-02-09 Impact factor: 56.272
Authors: H J Burstein; G Curigliano; S Loibl; P Dubsky; M Gnant; P Poortmans; M Colleoni; C Denkert; M Piccart-Gebhart; M Regan; H-J Senn; E P Winer; B Thurlimann Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Min Yi; Henry M Kuerer; Elizabeth A Mittendorf; Rosa F Hwang; Abigail S Caudle; Isabelle Bedrosian; Funda Meric-Bernstam; Jamie L Wagner; Kelly K Hunt Journal: J Am Coll Surg Date: 2012-11-02 Impact factor: 6.113
Authors: Karl Y Bilimoria; David J Bentrem; Nora M Hansen; Kevin P Bethke; Alfred W Rademaker; Clifford Y Ko; David P Winchester; David J Winchester Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Lynn T Dengel; Kimberly J Van Zee; Tari A King; Michelle Stempel; Hiram S Cody; Mahmoud El-Tamer; Mary L Gemignani; Lisa M Sclafani; Virgilio S Sacchini; Alexandra S Heerdt; George Plitas; Manuela Junqueira; Deborah Capko; Sujata Patil; Monica Morrow Journal: Ann Surg Oncol Date: 2013-08-22 Impact factor: 5.344
Authors: Jun Wang; Elizabeth A Mittendorf; Aysegul A Sahin; Min Yi; Abigail Caudle; Kelly K Hunt; Yun Wu Journal: PLoS One Date: 2014-02-25 Impact factor: 3.240